BidaskClub downgraded shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) from a strong-buy rating to a buy rating in a research report report published on Tuesday morning.

LMAT has been the subject of a number of other research reports. Zacks Investment Research raised shares of LeMaitre Vascular from a hold rating to a buy rating and set a $36.00 price objective for the company in a research note on Friday, April 28th. Stifel Nicolaus boosted their price objective on shares of LeMaitre Vascular from $25.00 to $29.00 and gave the stock a buy rating in a research note on Friday, April 28th. Canaccord Genuity reissued a buy rating and issued a $28.00 price objective on shares of LeMaitre Vascular in a research note on Thursday, April 27th. Craig Hallum started coverage on shares of LeMaitre Vascular in a research note on Tuesday, June 6th. They issued a hold rating and a $31.00 price objective for the company. Finally, Benchmark Co. downgraded shares of LeMaitre Vascular from a buy rating to a hold rating in a research note on Monday, July 10th. They noted that the move was a valuation call. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and an average target price of $29.33.

Shares of LeMaitre Vascular (LMAT) traded up 19.51% on Tuesday, hitting $33.94. The stock had a trading volume of 859,710 shares. LeMaitre Vascular has a 52-week low of $16.80 and a 52-week high of $35.24. The company has a 50-day moving average of $29.50 and a 200-day moving average of $26.71. The company has a market cap of $638.58 million, a P/E ratio of 48.49 and a beta of 0.63.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $0.23 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.17 by $0.06. LeMaitre Vascular had a net margin of 12.52% and a return on equity of 13.36%. The firm had revenue of $25.80 million during the quarter, compared to the consensus estimate of $25.42 million. During the same quarter in the previous year, the firm posted $0.14 earnings per share. The company’s revenue was up 15.2% on a year-over-year basis. On average, equities analysts anticipate that LeMaitre Vascular will post $0.70 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “BidaskClub Lowers LeMaitre Vascular, Inc. (NASDAQ:LMAT) to Buy” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.watchlistnews.com/bidaskclub-lowers-lemaitre-vascular-inc-nasdaqlmat-to-buy/1461843.html.

LeMaitre Vascular declared that its board has initiated a stock buyback program on Thursday, July 27th that permits the company to repurchase $7.50 million in outstanding shares. This repurchase authorization permits the medical instruments supplier to repurchase up to 1.4% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s management believes its shares are undervalued.

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Wednesday, August 23rd will be issued a $0.055 dividend. This represents a $0.22 annualized dividend and a yield of 0.65%. The ex-dividend date is Monday, August 21st. LeMaitre Vascular’s dividend payout ratio is currently 36.67%.

In other news, VP Michael T. Wijas sold 2,346 shares of the business’s stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $31.42, for a total transaction of $73,711.32. Following the sale, the vice president now directly owns 3,584 shares of the company’s stock, valued at $112,609.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Chairman George W. Lemaitre sold 87,342 shares of the business’s stock in a transaction on Wednesday, May 3rd. The shares were sold at an average price of $32.35, for a total transaction of $2,825,513.70. Following the sale, the chairman now directly owns 3,484,149 shares in the company, valued at $112,712,220.15. The disclosure for this sale can be found here. Insiders sold 317,805 shares of company stock worth $9,910,332 over the last ninety days. Corporate insiders own 23.70% of the company’s stock.

Several large investors have recently made changes to their positions in LMAT. Columbia Wanger Asset Management LLC raised its stake in shares of LeMaitre Vascular by 21.0% in the first quarter. Columbia Wanger Asset Management LLC now owns 1,093,903 shares of the medical instruments supplier’s stock worth $26,943,000 after buying an additional 189,608 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of LeMaitre Vascular by 2.1% in the first quarter. Dimensional Fund Advisors LP now owns 927,465 shares of the medical instruments supplier’s stock worth $22,843,000 after buying an additional 19,128 shares during the period. Vanguard Group Inc. raised its stake in shares of LeMaitre Vascular by 6.5% in the first quarter. Vanguard Group Inc. now owns 660,331 shares of the medical instruments supplier’s stock worth $16,264,000 after buying an additional 40,448 shares during the period. Conestoga Capital Advisors LLC raised its stake in shares of LeMaitre Vascular by 45.8% in the second quarter. Conestoga Capital Advisors LLC now owns 565,069 shares of the medical instruments supplier’s stock worth $17,641,000 after buying an additional 177,379 shares during the period. Finally, Thomson Horstmann & Bryant Inc. raised its stake in shares of LeMaitre Vascular by 1.8% in the second quarter. Thomson Horstmann & Bryant Inc. now owns 365,977 shares of the medical instruments supplier’s stock worth $11,425,000 after buying an additional 6,638 shares during the period. 66.45% of the stock is currently owned by hedge funds and other institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.